Nifty
:
23349.90
Sensex
:
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)
Nifty
Sensex
:
:
23349.90
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)

Wanbury Ltd.

Pharmaceuticals & Drugs

Rating :
N/A

BSE: 524212 | NSE: WANBURY

NSE BSE
160.45
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  169.23
  •  169.23
  •  159.20
  •  165.23
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  233472
  •  382.58
  •  290.20
  •  94.70

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 691.25
  • 13.05
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 855.06
  • N/A
  • 17.84

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 39.77%
  • 10.20%
  • 40.66%
  • FII
  • DII
  • Others
  • 1.02%
  • 0.00%
  • 8.35%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.70
  • 9.39
  • 4.04

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.57
  • -
  • 17.14

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 33.13
  • -2.79
  • -11.77

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 1.98
  • 2.70

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -1.68
  • -2.44
  • -3.26

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.85
  • 12.70
  • 10.17

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
161.19
144.46
11.58%
131.11
146.28
-10.37%
139.41
132.97
4.84%
145.50
125.78
15.68%
Expenses
141.18
127.12
11.06%
120.13
132.94
-9.64%
121.24
118.81
2.05%
124.35
119.32
4.22%
EBITDA
20.01
17.34
15.40%
10.97
13.35
-17.83%
18.16
14.16
28.25%
21.15
6.46
227.40%
EBIDTM
12.41%
12.01%
8.37%
9.12%
13.03%
10.65%
14.53%
5.13%
Other Income
1.63
0.76
114.47%
0.95
0.62
53.23%
0.93
-2.06
-
0.69
0.26
165.38%
Interest
10.15
7.67
32.33%
7.59
5.79
31.09%
7.46
7.52
-0.80%
8.26
6.63
24.59%
Depreciation
3.32
3.24
2.47%
3.29
3.19
3.13%
3.28
3.07
6.84%
3.32
3.13
6.07%
PBT
8.17
7.19
13.63%
1.04
4.99
-79.16%
33.91
0.92
3,585.87%
10.25
-3.04
-
Tax
0.15
-0.18
-
0.00
0.30
-100.00%
0.27
-0.10
-
-0.02
0.23
-
PAT
8.02
7.36
8.97%
1.04
4.69
-77.83%
33.63
1.02
3,197.06%
10.27
-3.28
-
PATM
4.97%
5.10%
0.79%
3.21%
24.13%
0.76%
7.06%
-2.61%
EPS
2.45
2.25
8.89%
0.32
1.43
-77.62%
10.27
0.31
3,212.90%
3.14
-1.00
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
577.21
575.65
499.65
511.19
392.52
367.45
391.37
371.10
433.81
423.26
249.92
Net Sales Growth
5.04%
15.21%
-2.26%
30.23%
6.82%
-6.11%
5.46%
-14.46%
2.49%
69.36%
 
Cost Of Goods Sold
289.53
302.63
303.44
300.28
221.33
175.74
196.20
174.09
196.97
182.40
119.30
Gross Profit
287.68
273.02
196.20
210.90
171.19
191.72
195.17
197.01
236.83
240.87
130.62
GP Margin
49.84%
47.43%
39.27%
41.26%
43.61%
52.18%
49.87%
53.09%
54.59%
56.91%
52.26%
Total Expenditure
506.90
505.65
476.57
479.45
376.85
389.07
378.00
439.03
415.28
390.89
228.50
Power & Fuel Cost
-
24.58
20.59
18.41
17.13
15.38
14.46
15.26
18.74
18.51
10.05
% Of Sales
-
4.27%
4.12%
3.60%
4.36%
4.19%
3.69%
4.11%
4.32%
4.37%
4.02%
Employee Cost
-
86.92
81.00
74.81
64.15
67.48
75.72
87.10
87.59
85.41
39.57
% Of Sales
-
15.10%
16.21%
14.63%
16.34%
18.36%
19.35%
23.47%
20.19%
20.18%
15.83%
Manufacturing Exp.
-
13.31
11.43
12.66
9.98
13.77
7.98
10.21
15.04
12.34
2.98
% Of Sales
-
2.31%
2.29%
2.48%
2.54%
3.75%
2.04%
2.75%
3.47%
2.92%
1.19%
General & Admin Exp.
-
26.59
22.72
20.58
23.63
28.56
30.47
29.66
34.37
29.80
25.49
% Of Sales
-
4.62%
4.55%
4.03%
6.02%
7.77%
7.79%
7.99%
7.92%
7.04%
10.20%
Selling & Distn. Exp.
-
26.65
21.27
31.31
16.86
19.63
27.41
29.49
42.43
34.19
15.15
% Of Sales
-
4.63%
4.26%
6.12%
4.30%
5.34%
7.00%
7.95%
9.78%
8.08%
6.06%
Miscellaneous Exp.
-
24.96
16.12
21.40
23.78
68.51
25.77
93.22
20.14
28.26
15.15
% Of Sales
-
4.34%
3.23%
4.19%
6.06%
18.64%
6.58%
25.12%
4.64%
6.68%
6.39%
EBITDA
70.29
70.00
23.08
31.74
15.67
-21.62
13.37
-67.93
18.53
32.37
21.42
EBITDA Margin
12.18%
12.16%
4.62%
6.21%
3.99%
-5.88%
3.42%
-18.31%
4.27%
7.65%
8.57%
Other Income
4.20
2.99
1.01
5.09
4.75
46.20
11.50
76.70
89.69
1.40
6.48
Interest
33.46
29.18
21.39
20.61
23.07
32.87
39.88
30.86
35.51
31.87
18.62
Depreciation
13.21
13.03
12.38
11.45
9.75
9.68
9.97
10.30
10.32
9.05
4.80
PBT
53.37
30.78
-9.69
4.76
-12.41
-17.97
-24.98
-32.39
62.40
-7.15
4.48
Tax
0.40
0.38
0.11
-0.35
0.20
0.21
-0.14
-0.38
0.38
0.00
1.27
Tax Rate
0.75%
0.67%
-1.07%
-0.43%
-1.61%
0.32%
0.56%
1.17%
0.61%
0.00%
28.35%
PAT
52.96
55.96
-10.40
81.47
-12.61
64.46
-24.85
-32.01
62.01
-7.15
3.20
PAT before Minority Interest
52.96
55.96
-10.40
81.47
-12.61
64.46
-24.85
-32.01
62.01
-7.15
3.20
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
9.18%
9.72%
-2.08%
15.94%
-3.21%
17.54%
-6.35%
-8.63%
14.29%
-1.69%
1.28%
PAT Growth
440.96%
-
-
-
-
-
-
-
-
-
 
EPS
16.15
17.06
-3.17
24.84
-3.84
19.65
-7.58
-9.76
18.91
-2.18
0.98

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
27.94
-32.82
-23.42
-156.24
-143.45
-209.28
-184.68
-153.28
-188.77
-193.94
Share Capital
32.75
32.71
32.67
25.02
25.00
23.72
23.72
23.22
19.97
19.97
Total Reserves
-11.64
-67.15
-57.01
-181.60
-168.66
-233.23
-208.66
-176.50
-220.96
-213.91
Non-Current Liabilities
95.95
10.81
10.56
84.43
107.74
130.36
105.79
159.92
251.37
298.18
Secured Loans
82.00
0.00
0.00
71.99
99.54
123.03
99.01
153.73
230.92
270.48
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
15.51
13.93
12.07
13.75
11.56
10.69
10.14
9.55
8.76
7.48
Current Liabilities
214.11
320.03
359.77
355.35
311.04
361.60
348.25
401.91
298.61
264.85
Trade Payables
162.75
148.71
179.56
133.77
121.87
112.24
83.13
140.11
86.11
99.15
Other Current Liabilities
33.36
153.93
162.35
200.56
160.75
160.69
178.59
194.50
118.92
85.47
Short Term Borrowings
14.95
13.19
13.21
16.42
24.92
85.21
82.67
63.19
90.60
77.85
Short Term Provisions
3.04
4.19
4.66
4.60
3.50
3.47
3.85
4.12
2.97
2.37
Total Liabilities
338.00
298.02
346.91
283.54
275.33
282.68
269.36
408.55
387.87
395.75
Net Block
166.82
167.11
167.11
167.38
163.90
172.36
178.33
186.34
180.27
164.05
Gross Block
248.41
239.29
226.95
215.98
203.10
202.03
198.61
196.65
325.72
305.65
Accumulated Depreciation
81.58
72.18
59.84
48.59
39.20
29.66
20.28
10.32
145.46
141.60
Non Current Assets
178.71
174.24
173.71
182.28
181.69
184.53
191.66
216.83
223.94
214.65
Capital Work in Progress
3.01
1.61
2.35
11.01
13.89
8.97
10.05
9.58
14.42
18.52
Non Current Investment
0.03
0.01
0.01
0.01
0.01
0.02
0.02
0.03
0.01
0.01
Long Term Loans & Adv.
5.42
5.03
3.80
3.40
3.80
3.11
2.84
20.46
28.98
31.08
Other Non Current Assets
3.44
0.49
0.44
0.46
0.10
0.07
0.41
0.43
0.26
0.99
Current Assets
159.29
121.81
171.24
97.53
93.64
98.15
77.70
191.73
163.93
181.11
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
36.02
21.99
49.73
24.85
12.26
19.33
13.07
34.23
34.61
33.77
Sundry Debtors
89.44
68.98
62.80
34.47
50.79
44.41
29.46
84.66
74.94
98.52
Cash & Bank
5.90
3.93
25.31
11.70
16.70
5.25
6.21
9.37
7.22
12.03
Other Current Assets
27.92
3.97
5.40
23.09
13.89
29.16
28.96
63.47
47.15
36.78
Short Term Loans & Adv.
21.27
22.94
28.00
3.42
4.47
2.69
6.27
37.16
29.41
16.51
Net Current Assets
-54.82
-198.22
-188.53
-257.82
-217.41
-263.44
-270.55
-210.19
-134.68
-83.74
Total Assets
338.00
296.05
344.95
279.81
275.33
282.68
269.36
408.56
387.87
395.76

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
3.98
19.80
40.52
16.68
44.13
29.73
32.49
43.39
43.05
40.17
PBT
56.34
-10.29
81.13
-12.41
64.67
-24.98
-32.39
62.40
-7.15
4.48
Adjustment
16.05
37.01
-43.68
33.22
-41.41
42.90
39.71
-37.29
47.85
22.65
Changes in Working Capital
-68.23
-6.75
3.24
-3.00
20.90
11.88
26.05
18.33
2.36
13.13
Cash after chg. in Working capital
4.16
19.97
40.69
17.81
44.16
29.80
33.37
43.43
43.07
40.25
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-0.18
-0.17
-0.16
-1.13
-0.03
-0.06
-0.89
-0.04
-0.01
-0.08
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-16.63
-8.84
0.59
8.04
63.66
-3.07
-1.39
-13.06
-19.63
-5.33
Net Fixed Assets
-10.52
-11.60
-2.31
-10.00
-5.99
-2.34
-2.43
133.91
-15.98
-1.45
Net Investments
-0.02
0.00
0.00
0.00
0.01
0.00
0.01
-0.02
0.00
0.00
Others
-6.09
2.76
2.90
18.04
69.64
-0.73
1.03
-146.95
-3.65
-3.88
Cash from Financing Activity
14.55
-31.99
-28.58
-17.39
-107.87
-26.78
-33.26
-26.93
-28.07
-29.54
Net Cash Inflow / Outflow
1.91
-21.03
12.52
7.34
-0.08
-0.13
-2.16
3.39
-4.65
5.29
Opening Cash & Equivalents
1.49
22.53
10.00
2.66
2.74
2.87
5.03
1.63
6.28
0.99
Closing Cash & Equivalent
3.40
1.49
22.53
10.00
2.66
2.74
2.87
5.03
1.63
6.28

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
6.44
-10.57
-7.55
-62.60
-57.48
-88.32
-77.97
-66.01
-112.21
-109.34
ROA
17.60%
-3.22%
25.85%
-4.51%
23.10%
-9.00%
-9.44%
15.57%
-1.82%
0.80%
ROE
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
ROCE
101.15%
29.82%
428.78%
87.61%
444.45%
50.26%
-2.00%
70.48%
15.27%
13.85%
Fixed Asset Turnover
2.38
2.18
2.32
1.88
1.83
2.08
2.00
1.70
1.37
0.83
Receivable days
49.78
47.23
34.50
39.45
46.85
32.42
52.61
65.66
72.98
144.54
Inventory Days
18.23
25.70
26.45
17.17
15.54
14.22
21.80
28.32
28.77
49.39
Payable days
187.82
197.43
190.42
210.79
243.11
106.12
125.89
110.93
100.14
182.52
Cash Conversion Cycle
-119.82
-124.50
-129.47
-154.17
-180.72
-59.49
-51.47
-16.96
1.60
11.41
Total Debt/Equity
5.21
-1.86
-2.72
-1.02
-1.14
-1.11
-1.19
-1.76
-1.67
-1.74
Interest Cover
2.93
0.52
4.94
0.46
2.97
0.37
-0.05
2.76
0.78
1.24

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Wanbury gets CEP for Dextromethorphan active pharmaceutical ingredient
    9th Sep 2024, 09:37 AM

    With the CEP certification, Wanbury is well positioned to initiate the commercial sales of this product in European markets

    Read More
  • Wanbury gets EIR from USFDA for Maharashtra manufacturing facility
    23rd Aug 2024, 10:12 AM

    Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.